Inhaled corticosteroids in COPD
123 results
101 - 123
Guidelines for COPD (ACP)
Population-based case-finding intervention to identify undiagnosed COPD and asthma has minimal benefits
Combination inhaled steroid and long‐acting beta2‐agonist versus tiotropium for chronic obstructive pulmonary disease
Tiotropium, inhaled steroids and long-acting beta2-agonists alone or in combinations for chronic obstructive pulmonary disease
Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
Beclometasone for chronic obstructive pulmonary disease: Cochrane systematic review
Phosphodiesterase‐4 inhibitors for chronic obstructive pulmonary disease
Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease
Canadian Thoracic Society guidelines for pharmacotherapy of stable chronic obstructive pulmonary disease
Long‐acting beta2‐agonists for chronic obstructive pulmonary disease
Vitamin D for the management of chronic obstructive pulmonary disease
Oral theophylline for chronic obstructive pulmonary disease
Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease
Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta2‐agonists or placebo for chronic obstructive pulmonary disease
Ipratropium bromide versus short acting beta‐2 agonists for stable chronic obstructive pulmonary disease
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Tiotropium versus long‐acting beta‐agonists for stable chronic obstructive pulmonary disease
Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma
Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta‐analysis
Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD)
